Russia’s cancer vaccine has successfully completed preclinical trials, demonstrating both safety and high efficacy, Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), announced at the Eastern Economic Forum (EEF).

"The research spanned several years, with the last three dedicated to mandatory preclinical studies," Skvortsova stated. "The vaccine is now ready for use; we are awaiting official approval."

She emphasised that preclinical results confirmed the vaccine’s safety, even with repeated administration, and its significant effectiveness.

Researchers observed reductions in tumour size and slowed tumour progression - ranging from 60% to 80% - depending on the disease characteristics. Additionally, studies indicated increased survival rates attributable to the vaccine.

The initial target for this vaccine will be colorectal cancer. Moreover, promising progress has been made in developing vaccines for glioblastoma and specific types of melanoma, including ocular melanoma, which are currently at advanced stages of development.

The 10th Eastern Economic Forum was held in Vladivostok on 3-6 September under the theme "The Far East: Cooperation for Peace and Prosperity."

The business programme featured more than 100 thematic sessions divided into seven tracks. The forum brought together over 8,400 participants from more than 75 countries and territories. The Roscongress Foundation was the organiser of the EEF, and TASS, its general information partner.